Intensive chemotherapy with high doses o
โ
M. H. Gaspard; D. Maraninchi; A. M. Stoppa; J. A. Gastaut; G. Michel; N. Tubiana
๐
Article
๐
1988
๐
Springer
๐
English
โ 688 KB
Twenty-six patients (median age 33 years) with poor-risk malignancies were treated with high-dose combination chemotherapy associating BCNU-etoposide-cytosine arabinoside and melphalan (BEAM) followed by autologous bone marrow transplantation (ABMT). Twenty-one patients had malignant lymphomas, thre